Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Hepatitis C, Chronic 2Hepatitis C 2Recurrence 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Liver Diseases 1Hepatitis 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Sofosbuvir × Clear all
NCT02959359 2017-08-07

DAA in the Risk of Recurrence After Curative Treatment of HCC

Taipei Veterans General Hospital, Taiwan

Phase 4 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡